Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

• Status: Terminated
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: 3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido(3,4-b)pyrazin-2(1H)-one

Criteria

Inclusion Criteria:

• Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female.

• Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI.

• Stroke involving upper extremity.

• Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable.

Exclusion Criteria:

• Any other severe acute or chronic medical or psychiatric condition besides the stroke.

• Women of child bearing potential.

• Uncontrolled hypertension.